Melanoma Trial, Recruiting NCT00040352 Sponsor: National Cancer Institute (NCI) Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT00040352
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 4 weeks or older, of any sex, race, or ethnicity, who have a personal history of melanoma (a type of skin cancer) that is unusual in its type, pattern, or number of occurrences, diagnosed at any age
  • People with known or suspected factors that may increase their risk of melanoma, such as certain genetic or physical conditions present from birth (for example, large birthmarks called giant congenital nevi, abnormal moles called dysplastic nevi, or certain unusual skin growths called Spitzoid tumors)
  • People with unusual personal health history features that may be linked to higher melanoma risk, such as being very young at diagnosis, having had multiple melanomas, or having a history of heritable retinoblastoma, Hodgkin's disease, lymphoma, a weakened immune system, or an organ transplant
  • People who do not personally have melanoma but have a family history of melanoma that is unusual in type, pattern, or number
  • People without melanoma who have family members with the risk factors or unusual health history features listed above
  • People who are able to understand and agree to participate, or whose parent or legal guardian is able to understand and agree on their behalf
  • Personal and family medical history must be able to be confirmed through questionnaires, interviews, medical records, and review of tissue samples

Who may not be able to join:

  • People or families whose reported diagnoses cannot be confirmed through medical records or other verification
  • People who are unable to provide informed consent, and for whom a parent or legal guardian is also unable to provide consent on their behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael R Sargen, M.D., National Cancer Institute (NCI)

Phone: (800) 518-8474

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2002

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

All cancers that occur in individuals and families at high risk of melanoma

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov